Viatris Inc.
https://www.viatris.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Viatris Inc.
Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Who’s Hired? Apotex Names New US President & CEO
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
500 Days Later: Every Step Of Mylan And Upjohn’s Merger Into Viatris
Viatris, the combination of Mylan and Pfizer’s Upjohn unit, launched on 16 November. The culmination of almost 16 months of work, the transaction faced many hurdles, not least the devastating effects of the novel coronavirus pandemic. Generics Bulletin has collated every step of the deal in chronological order, spanning its 476-day history.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Transdermal
- Other Names / Subsidiaries
-
- Acton Pharmaceuticals, Inc.
- Agila, Bioniche Pharma Holdings Limited
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Bertek
- Dow B. Hickham
- Dow Hickam Pharmaceuticals, Inc.
- Generics (UK) Ltd.
- Jai Pharma
- Madaus Pharma
- Meda AB
- Meda Pharmaceuticals Inc.
- Mylan Inc.
- Mylan Laboratories Limited (formerly Matrix Laboratories Limited)
- Mylan Specialty (formerly Dey Pharma L.P.)
- Rottapharm Madaus
- Mylan Technologies, Inc.
- UDL Laboratories
- Viatris Inc.